JP Morgan Chase
SPRY icon

JP Morgan Chase’s ARS Pharmaceuticals SPRY Stock Holding History

JP Morgan Chase’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-80,000
Closed -$804K – 7753
2025
Q3 		$804K Buy
+80,000
New +$1.15M ﹤0.01% 4745

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase's SPRY Position: Q2 2026 in Review

JP Morgan Chase reduced its ARS Pharmaceuticals (SPRY) stake by 5.1% in Q2 2026, selling an estimated $168K and leaving 363,316 shares worth $3.11M. The position accounts for ﹤0.01% of the portfolio, ranked #3857.

JP Morgan Chase first reported a position in SPRY in Q1 2021 and has held it in 22 quarters since. The position peaked at $4.86M in Q4 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • JP Morgan Chase held 363,316 shares of ARS Pharmaceuticals worth $3.11M as of Q2 2026.
  • JP Morgan Chase sold 19,485 ARS Pharmaceuticals shares in Q2 2026, an estimated $168K.
  • ARS Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3857 holding.
  • JP Morgan Chase first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • JP Morgan Chase's ARS Pharmaceuticals position peaked at $4.86M in Q4 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.